Enzalutamide (XTANDI) has an unshakable position in the treatment of metastatic prostate cancer, and clinicians treating patients with advanced prostate cancer internationally are also very interested in enzalutamide. Familiar, becoming the standard of care for metastatic castration-resistant prostate cancer. Research shows that early first-line treatment of metastatic prostate cancer has higher antigen response rates, longer survival, and lower risk of fatigue.

https://www.medixocentre.com/enzalutamide-40-mg